HISOAR(SZ:002099) Xin Lang Cai Jing·2026-01-09 01:59Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical has experienced a significant stock price increase, rising 7.58% on January 9, with a total market value of 11.946 billion yuan and a cumulative increase of 9.94% over four consecutive days [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The company's main business revenue composition includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position, having reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which is 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100), established on September 29, 2016, has a current scale of 76.63 billion yuan, with a year-to-date return of 4.96% and a one-year return of 42.74% [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a tenure of 7 years and 65 days, with a total asset scale of 122.76 billion yuan, achieving a best return of 208.53% and a worst return of -15.93% during the tenure [3]